Business · 12/01/2022Updated: 10/17/2026 · 1 min read
FDA Corrects Patent Extension Review Period for ENHERTU
Summary
The FDA has updated its notice on the regulatory review period for patent extension of the human biological product ENHERTU, correcting an initial determination published in 2021.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →